|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
All tumors were associated with normal or low serum alpha fetoprotein levels, and showed an absence of immunohistochemical staining of hepatocellular markers (Hep-par1, Arginase) and loss of INI1 staining.
|
31835848 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The recognition that PAR1 actively limits pancreatic cancer cell growth suggest that the contributions of PAR1 to tumor growth differ between cancers of epithelial origin and that its targeting should be applied with care.
|
30174793 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Objective To analyze the role of PAR-1 in the setting of two distinct spontaneously developing tumor models in mice.
|
30152921 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Using the chick CAM models, we further showed that inhibition of PAR-1 suppressed tumor growth and giant cell formation in vivo.
|
28670703 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Using a model of subcutaneous implantation of MDA-MB-231 cells in nude mice, PAR1-PR enhanced tumour growth more markedly than PAR4-PR, and seemed to achieve the exaggeration by promoting more profound tumour angiogenesis.
|
28697175 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PAR-1 is expressed not only in epithelium, neurons, astrocytes, immune cells, but also in cancer-associated fibroblasts, ECs (epithelial cells), myocytes of blood vessels, mast cells, and macrophages in tumor microenvironment, whereas PAR-1 stimulates macrophages to synthesize and secrete thrombin as well as other growth factors, resulting in enhanced cell proliferation, tumor growth and metastasis.
|
29291033 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Overall, our data provide evidence that PAR-1 in NSCLC is mainly expressed on cells that constitute the pulmonary tumor microenvironment, including vascular endothelial cells, macrophages and stromal fibroblasts.
|
28173772 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this study, we aimed to explore if dabigatran may affect mechanisms favoring tumor growth by interfering with thrombin-induced PAR-1 activation.
|
27600331 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Collectively, our findings established a functional role for thrombin and its targets PAR-1 and fibrinogen in the pathogenesis of colonic adenocarcinoma, supporting tumor growth as well as local invasion and metastasis.
|
26238780 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Taken together, our observations show that PAR1 and PAR2 act as a functional unit in tumor development and placenta-uterus interactions.
|
24177339 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The protein level of PAR-1 was significantly correlated with tumor size only, while the VEGF protein level was significantly correlated with invasion depth and tumor size.
|
24817013 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
F3/TF and F2R/PAR-1 mRNA expression are upregulated in SHH tumors and correlate with higher levels of hepatocyte growth factor receptor (MET).
|
25163932 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PAR-1 enhances monocyte recruitment into the tumor microenvironment by regulating monocyte migration and fibroblast dependent chemokine production thereby inducing chemoresistance.
|
24436106 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Using an immunohistochemical approach with gastric carcinoma tissue, we found the expression of protease-activated receptor-1 (PAR1), along with a metalloproteinase known to activate PAR1, were associated with poorer prognosis, compared with expression-negative tumors, and activated PAR1 promotes gastric cancer cell invasion and proliferation in vivo.
|
25231630 |
2014 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The PAR-1 -14 Ivs A/A genotype was associated with advanced tumor stages (p = 0.024) and, in univariate analysis, with shorter median OS in squamous cell lung carcinoma (SqCC, p = 0.035).
|
23548249 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The inhibitory effects of specific PAR1 antagonists in live animals have also indicated that the mechanisms of MMP-1-dependent vascular permeability in tumors involve endothelial PAR1 activation.
|
23687338 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Overall, our results enlighten the mechanism by which tissue factor promotes tumor growth through PAR1, and they show how EPCR can attenuate the growth of tissue factor-expressing tumor cells.
|
23539451 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PAR-1 mediates angiogenesis and impacts the process of tumor growth and disease progression.
|
23517743 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We showed that stimulation of proteinase-activated receptor-1 (PAR1) can trigger an array of responses that would promote tumor cell growth and invasion.
|
23242308 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
By deregulating protease activated receptors (PAR1/2) oncogenes may also change tumour cell responses to coagulation factor signalling.
|
22682129 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In turn, the thrombin receptor, PAR-1, regulates the expression of the gap junction protein Connexin-43 and the tumor suppressor gene Maspin.
|
21147226 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The role of PAR(1) in tumor biology has been established, and is characterized by a consistent direct correlation between overexpression of its levels and epithelial tumor aggressiveness.
|
21557443 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Recently, PAR-1 has been described to regulate the gap junction protein Connexin 43 and the tumor suppressor gene Maspin to promote the metastatic melanoma phenotype.
|
21378407 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
More importantly, PAR3(-/-) cells, in contrast to PAR1(-/-) ones, formed larger tumors in immunodeficient mice.
|
20442298 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our data indicate that in gastric carcinoma cells, PAR1 activation can trigger an array of responses that would promote tumor cell growth and invasion.
|
20723226 |
2010 |